Clinical Trial Update: Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) [Phase 2]

View source ↗

Summary

Phase 2 study assessing Imprime PGG in combination with pembrolizumab in HR+/HER2- metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Imprime PGG
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: HiberCell, Inc. | Conditions: Malignant Neoplasm of Breast | Phase 2 | Status: COMPLETED